Month: July 2021

Formulation-related observations from ARQ-252 trial in chronic hand eczema informed early termination of Phase 2a ARQ-252 trial in vitiligo Company progressing new formulation with goal of greater drug delivery to targets in the skinWESTLAKE VILLAGE, Calif., July 01, 2021 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), today announced its decision to terminate the recently initiated Phase 2a clinical trial evaluating ARQ-252, a topical small molecule inhibitor of Janus kinase type 1 (JAK1), as a potential treatment for vitiligo (ARQ-252-213). Arcutis’ decision is based on further analyses of the ARQ-252 drug formulation used in both this vitiligo study and the recently completed Phase 2b study evaluating ARQ-252 for the treatment of chronic hand eczema (ARQ-252-205). As previously announced, the Phase 2b chronic...

VIRGINIA BEACH, Va., July 01, 2021 (GLOBE NEWSWIRE) — Armada Hoffler Properties, Inc. (NYSE: AHH) will report its earnings for the quarter ended June 30, 2021 at approximately 6:00 a.m. Eastern on Tuesday, August 3, 2021. At 8:30 a.m. Eastern on the same day, senior management will host a conference call and webcast to discuss earnings and other information. To listen to the call, dial 877-407-3982 (domestic) or 201-493-6780 (international) approximately 10 minutes prior to the start time of the call. The conference call will also be available through the investors page of the Company’s website, ArmadaHoffler.com. A telephonic replay will be available shortly after the conclusion of the call through Friday, September 3, 2021. This replay may be accessed by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and providing...

Aiming to facilitate long distance, reliable, secured communications SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) — GBT Technologies Inc. ( OTC PINK: GTCH ) (“GBT” or the “Company”), is now evaluating and testing a hybrid solution for an efficient, long range coverage for its Infinia Long Range radio system.  Guided by rules of physics, the lower the frequency is, the greater distance it can travel, yet low frequencies are sensitive to other issues. VHF (Very High Frequency) and UHF (Ultra High Frequency) radio waves travel in LOS (“Line-of-Sight”), which defines their maximum communication range. High frequency (HF) radio communications can reach beyond line of sight by using the ionosphere to refract radio signals back to earth. GBT is now conducting a hybrid-evaluation and testing to combine the two frequency’s ranges...

Administration of OC-01 (varenicline) nasal spray to non-human primates was observed to inhibit viral replication in the nose within 24 hours of infectious SARS-CoV-2 challenge with absence of subgenomic RNA at Day 3 and Day 5 post-challengeVarenicline inhibits cellular entry and replication of SARS-CoV-2 and its alpha and beta variants in multiple human cell typesSimpinicline inhibits cellular entry and replication of SARS-CoV-2 alpha variant in Calu-3 human cells with additional variants under investigationOyster Point Pharma collaborates with the Trudeau Institute for in vitro testing of varenicline, the active ingredient in OC-01 nasal spray and simpinicline, the active ingredient in OC-02 nasal sprayOyster Point Pharma plans to present data at the upcoming Analyst Day, scheduled for July 15, 2021PRINCETON, N.J., July...

– U.S. FDA has assigned a target action date of April 30, 2022 – – If approved, surufatinib would be HUTCHMED’s first novel oncology drug marketed outside of China – HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 01, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the U.S. Food and Drug Administration (“FDA”) has accepted its filing of the New Drug Application (“NDA”) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors (“NETs”). The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for this NDA is April 30, 2022. Surufatinib received fast track designation in April 2020 for the treatment of pancreatic and extra-pancreatic NET. Orphan Drug Designation for pancreatic NET was also granted...

SHENZHEN, China, July 01, 2021 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading mobile developer service provider in China, today announced that it has entered into a partnership agreement with Hefei Weitian Yuntong Information Technology Co. Ltd. (“Hefei Weitian”), a leading logistics information service provider. Aurora Mobile will help Hefei Weitian by providing Video-as-a-Service solutions (“JG VaaS”) to boost user acquisition and engagement for its trucking logistics APP – Haoyunbao. In China, about 80% of the trucking logistics industry is undertaken by independent truckers. They face a number of challenges such as insecure job environment, low shipping rates, long distance solo driving, limited access to emergency services and road rescue services. Designed...

Company Announcement COPENHAGEN, Denmark; July 01, 2021 – Genmab A/S (Nasdaq: GMAB) announces that its share buy–back program has been completed on June 30, 2021. On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program. The share buy-back program was expected to be completed no later than June 30, 2021 and comprised up to 200,000 shares. The following transactions were executed under the program from June 28, 2021, to June 30, 2021:  No. of shares Average price (DKK) Total value (DKK)Accumulated through last announcement 193,400  429,072,364June 28, 2021 3,000 2,609.07 7,827,210June 29, 2021 2,000 2,601.09 5,202,180June 30, 20211,6002,580.804,129,280Total 6,600   17,158,670Accumulated...